A Phase I, Open-Label, Multi-center, Competitive Enrollment and Dose-escalation Study of ALT-836 in Combination With Gemcitabine for Locally Advanced or Metastatic Solid Tumors

Trial Profile

A Phase I, Open-Label, Multi-center, Competitive Enrollment and Dose-escalation Study of ALT-836 in Combination With Gemcitabine for Locally Advanced or Metastatic Solid Tumors

Completed
Phase of Trial: Phase I

Latest Information Update: 30 Aug 2017

At a glance

  • Drugs ALT 836 (Primary) ; Gemcitabine
  • Indications Solid tumours
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Altor BioScience Corporation
  • Most Recent Events

    • 13 Jul 2016 Status changed from active, no longer recruiting to completed.
    • 08 Dec 2015 Planned End Date changed from 1 Sep 2015 to 1 Feb 2016 as reported by ClinicalTrials.gov record.
    • 03 Aug 2015 Planned End Date changed from 1 Jun 2015 to 1 Sep 2015, as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top